![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Health-Related Quality of Life Among People Receiving Opioid Agonist Therapy and Treatment for Hepatitis C Virus Infection:
Results From CO-STAR
|
|
|
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Olav Dalgard1; Gregory J. Dore2; Oren Shibolet3; Jason Grebely2; Ronald Nahass4; Frederick L. Altice5; Brian Conway6; Edward J. Gane7; Anne Luetkemeyer8; Cheng-Yuan Peng9; David Iser10; Isaias Noel Gendrano11; Michelle M. Kelly11; Barbara A. Haber11; Heather Platt11; Amy Puenpatom11
1Akershus University Hospital, Lørenskog, Norway; 2The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; 3Liver Unit, Department of Gastroenterology, Tel Aviv Medical Center and Tel Aviv University, Tel Aviv, Israel; 4ID Care, Hillsborough, NJ, USA; 5Yale University, New Haven, CT, USA; 6Vancouver Infectious Diseases Centre, Vancouver, BC, Canada; 7Auckland City Hospital, Auckland, New Zealand; 8University of California, San Francisco, San Francisco, CA, USA; 9China Medical University Hospital, Taichung, Taiwan; 10The Alfred Hospital, Melbourne,
VIC, Australia; 11Merck & Co., Inc., Kenilworth, NJ, USA
![0904201](../images/090420/090420-6/0904201.gif)
![0904202](../images/090420/090420-6/0904202.gif)
![0904203](../images/090420/090420-6/0904203.gif)
![0904204](../images/090420/090420-6/0904204.gif)
![0904205](../images/090420/090420-6/0904205.gif)
![0904206](../images/090420/090420-6/0904206.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|